A Study of Transplant Organ Genomics to Help Prevent Rejection in Kidney Transplant Recipients with Realtime Assay Monitoring

Overview

About this study

The purpose of this study is to connect the findings of TruGraf (a peripheral blood RNA signature that has been shown to correlate with rejection in kidney transplants) with rejection episodes in kidney transplant patients that are managed using standard of care clinical protocols at the three Mayo transplant sites.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

Adult ≥ 18 years
A conventional solitary kidney transplant recipient (ABO compatible, crossmatch negative, not a kidney transplant simultaneously transplanted with another non-renal organ including heart, liver, lung or pancreas) who receives from a living or deceased donor
Has given informed consent and is willing and able to undergo peripheral blood collection at the specified time points and willing to participate in follow-up

Exclusion Criteria

Multiorgan transplant (ex.SLK, SPK) or prior recipient of non-renal transplant
EBV seronegative recipients
ABO incompatible kidney transplants
Simultaneous kidney and extra-renal organ transplants including pancreas, liver, heart, lung, bone marrow transplantation, etc. or prior recipient of non-renal transplant
- Previous extra renal transplants may be included in the study
Positive crossmatch kidney transplants
- T cell crossmatch >100
- B flow cytometric crossmatch >150
Participating in other clinical trials
Any kidney transplant recipient < 18 years of age

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Mark Stegall, M.D.	Closed for enrollment	Contact information: Jordan Scheevel Scheevel.Jordan@mayo.edu
Scottsdale/Phoenix, Ariz. Mayo Clinic principal investigator Raymond Heilman, M.D.	Closed for enrollment	Contact information: Samantha Parker D.T.R. (480) 342-6677 Parker.Samantha@mayo.edu
Jacksonville, Fla. Mayo Clinic principal investigator Martin Mai, M.D.	Closed for enrollment	Contact information: Joel Espinoza Espinoza.Joel@mayo.edu

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Mark Stegall, M.D.

Closed for enrollment

Contact information:

Jordan Scheevel

Scheevel.Jordan@mayo.edu

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Raymond Heilman, M.D.

Closed for enrollment

Contact information:

Samantha Parker D.T.R.

(480) 342-6677

Parker.Samantha@mayo.edu

Jacksonville, Fla.

Mayo Clinic principal investigator

Martin Mai, M.D.

Closed for enrollment

Contact information:

Joel Espinoza

Espinoza.Joel@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials